Edition:
United Kingdom

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

130.21USD
15 Dec 2017
Change (% chg)

$-0.61 (-0.47%)
Prev Close
$130.82
Open
$131.34
Day's High
$132.00
Day's Low
$128.50
Volume
173,494
Avg. Vol
107,048
52-wk High
$136.93
52-wk Low
$92.77

Latest Key Developments (Source: Significant Developments)

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - GW Pharmaceuticals Plc ::GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S..GW PHARMACEUTICALS - NOW REACQUIRED FULL OWNERSHIP OF DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT IN U.S. WITHOUT UPFRONT PAYMENT TO OTSUKA​.GW PHARMACEUTICALS - ‍AGREED TO MAKE CONTINGENT MILESTONE PAYMENTS TO OTSUKA, FIRST OF WHICH WOULD BECOME DUE UPON FDA APPROVAL OF SATIVEX​.GW PHARMACEUTICALS PLC - ‍TERMINATION OF PREVIOUS LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO IN RELATION TO SATIVEX IN U.S.​.  Full Article

GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Gw Pharmaceuticals Plc ::GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.GW PHARMACEUTICALS PLC - INTENDS TO SELL $225 MILLION OF AMERICAN DEPOSITARY SHARES.  Full Article

GW Pharma says second positive phase 3 trial for epidiolex in LGS
Monday, 26 Sep 2016 

Gw Pharmaceuticals Plc : Second positive phase 3 trial for Epidiolex in LGS . Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo . Expects to submit a new drug application to U.S. Food & Drug Administration in first half of 2017. . Data represents third positive phase 3 pivotal trial for epidiolex reported in 2016 . Second positive phase 3 pivotal trial for epidiolex cannabidiol in treatment of Lennox-Gastaut Syndrome .During treatment period, patients taking epidiolex 20mg/kg/day achieved median reduction in monthly drop seizures of 42 percent.  Full Article

GW Pharmaceuticals Q3 rev down sharply as Sativex R&D fees falls
Tuesday, 9 Aug 2016 

GW Pharmaceuticals Plc : 3Rd quarter results . Positive FDA pre-NDA meeting - NDA for dravet syndrome and LGS on track for h1 2017 submission . Loss for nine months ended 30 June 2016 of £46.7 million ($62.2 million) compared to £32.3 million for nine months ended 30 June 2015 . Cash and cash equivalents at 30 June 2016 of £191.2 million ($254.3 million) compared to £234.9 million as at 30 september 2015 . Plans to continue expansion of epidiolex plant growing capacity well beyond this 2016 goal . Total revenue for three months to 30 June 2016 was £2.3 million, compared to £8.6 million for three months ended 30 June 2015 . Remains on track to meet expenditure guidance given with its Q2 results in May 2016 . Exchange rate gain of £11.2 million experienced in Q3 has reduced projected net cash outflow for 2016 financial year .Subject to further exchange rate related volatility group's Q4 expenditure plans remain consistent with previous guidance.  Full Article

GW Pharmaceuticals says chief medical officer to retire
Tuesday, 9 Aug 2016 

Gw Pharmaceuticals Plc : Stephen Wright has notified GW's board of directors of his intention to retire .Wright plans to step down from his position as chief medical officer and a member of board of directors on 1 May 2017.  Full Article

GW Pharma says to raise $252 mln via public offering
Wednesday, 13 Jul 2016 

GW Pharmaceuticals Plc : GW Pharmaceuticals Plc announces pricing of U.S. public offering of American Depositary Shares (ADS) raising $252.0 mln on Nasdaq global market . Closing of offering is expected to occur on July 18, 2016 . Morgan Stanley, BofA Merrill Lynch and Goldman, Sachs & Co. are acting as joint book-running managers for offering . Cowen and Company is acting as lead manager and Piper Jaffray is acting as manager .Will issue 2.8 mln ADSs representing 33.6 mln shares of GW, at $90 per ADS.  Full Article

GW Pharmaceuticals announces positive phase 3 pivotal study results for Epidiolex
Monday, 14 Mar 2016 

GW Pharmaceuticals:Announces positive phase 3 pivotal study results for Epidiolex for the treatment of Dravet syndrome.In this study, Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo.Says Epidiolex has both orphan drug designation and fast track designation from U.S. Food and Drug Administration in treatment of Dravet syndrome.Says results from secondary efficacy endpoints reinforced the overall effectiveness observed with Epidiolex.Says Epidiolex was generally well tolerated in this study.  Full Article

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.